Cambium Bio Executes Agreement for Contract Manufacturing of Active Biologic Ingredient for Therapy Candidate

MT Newswires Live09-30

Cambium Bio (ASX:CMB) executed a memorandum of understanding with Taiwan-based Locus Cell for the contract manufacturing of the active biologic ingredient for Elate Ocular, its lead dry eye disease therapy candidate, according to a Tuesday Australian bourse filing.

Locus Cell will manufacture the active biologic ingredient, the drug substance component of Elate Ocular, based on pooled fibrinogen-depleted human platelet lysates.

Zheng Yang Biomedical Technology, as Cambium's technology partner, will provide manufacturing protocols and conduct technical transfer to Locus Cell. Zheng Yang holds around 28.1% stake in Cambium.

The manufacturing rights cover worldwide markets except Europe and the Middle East. Supply will be exclusively to Cambium or its designees under future definitive supply and quality deals. The agreement has a two-year initial term with mutual extension options.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2571394085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 12:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571394085","market":"sg","top_or_hot":-1,"title":"Cambium Bio Executes Agreement for Contract Manufacturing of Active Biologic Ingredient for Therapy Candidate","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CMB.AU\">Cambium Bio</a> (ASX:CMB) executed a memorandum of understanding with Taiwan-based Locus Cell for the contract manufacturing of the active biologic ingredient for Elate Ocular, its lead dry eye disease therapy candidate, according to a Tuesday Australian bourse filing.</p><p>Locus Cell will manufacture the active biologic ingredient, the drug substance component of Elate Ocular, based on pooled fibrinogen-depleted human platelet lysates.</p><p>Zheng Yang Biomedical Technology, as Cambium's technology partner, will provide manufacturing protocols and conduct technical transfer to Locus Cell. Zheng Yang holds around 28.1% stake in Cambium.</p><p>The manufacturing rights cover worldwide markets except Europe and the Middle East. Supply will be exclusively to Cambium or its designees under future definitive supply and quality deals. The agreement has a two-year initial term with mutual extension options.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cambium Bio Executes Agreement for Contract Manufacturing of Active Biologic Ingredient for Therapy Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCambium Bio Executes Agreement for Contract Manufacturing of Active Biologic Ingredient for Therapy Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-30 12:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CMB.AU\">Cambium Bio</a> (ASX:CMB) executed a memorandum of understanding with Taiwan-based Locus Cell for the contract manufacturing of the active biologic ingredient for Elate Ocular, its lead dry eye disease therapy candidate, according to a Tuesday Australian bourse filing.</p><p>Locus Cell will manufacture the active biologic ingredient, the drug substance component of Elate Ocular, based on pooled fibrinogen-depleted human platelet lysates.</p><p>Zheng Yang Biomedical Technology, as Cambium's technology partner, will provide manufacturing protocols and conduct technical transfer to Locus Cell. Zheng Yang holds around 28.1% stake in Cambium.</p><p>The manufacturing rights cover worldwide markets except Europe and the Middle East. Supply will be exclusively to Cambium or its designees under future definitive supply and quality deals. The agreement has a two-year initial term with mutual extension options.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMB.AU","symbol_name":"Cambium Bio Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2571394085","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571394085","pubTimestamp":1759205825,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cambium Bio  executed a memorandum of understanding with Taiwan-based Locus Cell for the contract manufacturing of the active biologic ingredient for Elate Ocular, its lead dry eye disease therapy candidate, according to a Tuesday Australian bourse filing.Locus Cell will manufacture the active biologic ingredient, the drug substance component of Elate Ocular, based on pooled fibrinogen-depleted human platelet lysates.Zheng Yang Biomedical Technology, as Cambium's technology partner, will provide manufacturing protocols and conduct technical transfer to Locus Cell. Zheng Yang holds around 28.1% stake in Cambium.The manufacturing rights cover worldwide markets except Europe and the Middle East. Supply will be exclusively to Cambium or its designees under future definitive supply and quality deals. The agreement has a two-year initial term with mutual extension options.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMB.AU":"Cambium Bio Limited","BK7067":"生物科技"},"translate_title":"Cambium Bio签署候选疗法活性生物成分合同生产协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMB.AU":1},"content_text":"Cambium Bio (ASX:CMB) executed a memorandum of understanding with Taiwan-based Locus Cell for the contract manufacturing of the active biologic ingredient for Elate Ocular, its lead dry eye disease therapy candidate, according to a Tuesday Australian bourse filing.Locus Cell will manufacture the active biologic ingredient, the drug substance component of Elate Ocular, based on pooled fibrinogen-depleted human platelet lysates.Zheng Yang Biomedical Technology, as Cambium's technology partner, will provide manufacturing protocols and conduct technical transfer to Locus Cell. Zheng Yang holds around 28.1% stake in Cambium.The manufacturing rights cover worldwide markets except Europe and the Middle East. Supply will be exclusively to Cambium or its designees under future definitive supply and quality deals. The agreement has a two-year initial term with mutual extension options.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571394085","isCrawlerRequest":true}